Jeanne is a well-versed patient advocate with a pioneering sense of the web’s potential to improve health care. Through her broad-based experience as a math and computer science teacher and healthcare website developer, she created the first and largest global social media cystic fibrosis patient community in 1996. Jeanne understands the complex issues patients with cystic fibrosis face. She is an expert in creating effective patient-centered website forums, videos, newsletters, and new technologies for patient education and self-care management. She is skilled in preparing and delivering comprehensive presentations to varied audiences including Pharma Conferences. She has recently chaired and/or delivered presentations at Digital Pharma East, Panagora Pharma, the World Orphan Drug Summit and eye for pharma. Jeanne won the Patient Centricity Award in 2011 from Pharma Phorum. She has a teacher’s patience and curiosity and quickly identifies and addresses the needs of patients requiring innovative technological solutions. In the patient insights space, she is detail-oriented with proven effectiveness in stimulating the patient base and is proactive in promoting the implementation of remote technology solutions, reducing cross contamination health risks and ultimately reducing chronic care costs. She is a graduate of Fordham University. Jeanne is a founding member of the Aurora Project. In her spare time, Jeanne (a birder) explores the neighborhoods, parks, and museums of NYC and its surrounding towns with her husband and grandchildren.

Blockchain for patient Identity, Rare Diseases

Terence Hoey, CEO/Founder of The Ultra Rare Disease Disorders And Disabilities Foundation we are a charity our cause is huge we want research into rare and ultra rare diseases we also want drug companies to cut the cost of drugs for rare and ultra rare diseases.

Rare and Ultra Rare Diseases

Translational Medicine, Clinical Pharmacology and Clinical Development, Project Management and Team Leader experience for more than 10 years in the area of Rare Diseases. Academic background of more than 15 years, especially in the field of Rare Diseases, Human and Veterinary Pharmacology and Molecular Pharmacology.

Research in molecular pharmacology, intracellular membrane protein transport, signal transduction, pharmacodynamics and pharmacokinetics.

Vesna Aleksovska has a background in journalism, non-government sector, project management and business consulting and around 10 years of experience in patient organizations and advocating for patients’ rights. She founded the Association of citizens for rare diseases “LIFE WITH CHALLENGES” – Bitola in 2009. She is a Gaucher patient and patient advocate for rare disease patient in R. Macedonia. Aleksovska is also co – founder and former President of the National Alliance for Rare Diseases of R. Macedonia from 2014. She is now in the board of NARDM and also in the board of the Alliance of Patient Organizations of Macedonia. In 2013 she become a member of the DITA (Drug Information, Transparency and Access) Task Force EURORDIS (European Organization for Rare Diseases) and a Vice chair and director in the board of directors of the International Gaucher Alliance since 2014. She is also a EUPATI (European Patients Academy on Therapeutic Innovation) fellow, trainer and EUPATI Ambassador for Macedonia. Vesna works in the field of advocacy and lobbying for rights of the rare disease patients in R. Macedonia through cooperation and communication with organizations and institutions (government and non-government) on national and international level. She believes that through strengthening patients and raising public awareness about rare diseases the world can become a better place to live in for patients and families that face life filled with challenges.

Wide knowledge in different fields as: business consulting, non-formal education, journalism, public relations, citizen organization management and action, capacity building of citizen organizations, fundraising, project cycle management, business consulting, culture, economy and health system issues (rare diseases). Well organized, experienced in project coordination, highly developed communication skills, good management and leadership skills, adaptation skills, with desire to learn and develop personally and professionally.

Bert Verhage initially worked as a hospital physician. He headed the foundation known as Transmuraal Netwerk from 2005 to 2009, which promotes the integration of healthcare services in Holland, before switching to the pharmaceutical industry.

Internal medicine, gastroenterology, osteoporosis, endocrinology, orphan drugs, food for special medical purpose, over the counter drugs, self medication, pharmaceutical company, tenders, named patient, pharmacovigilance, regulatory, medical devices, ISO, GDP, GMP, ICH, HACCP, GCP, trading, logistics and Brexit / pharma.

Tiziana Greggi Specialized works in Orthopedics and Traumatology, at the University of Bologna, Specialized in Biomedical Technologies, at the University of Bologna and she is the Head of Simple Departmental Structure: Spinal deformity surgery. She has worked in the Division of Spine Surgery of the Rizzoli Institute, first as an assistant and then as a senior manager. From 2000 to 2008 he received temporary positions as Director of a complex structure. From the end of this position to date has been responsible for the Organizational Module "the spinal deformities in pediatric age and associated with rare diseases" in the same Division. He is also responsible for a specialized clinic dedicated to the study and treatment of severe spinal deformities associated with rare diseases at the Rizzoli Orthopedic Institute. He is currently Head of the Departmental Simple Structure: Spinal deformity surgery

Spinal deformit, Spinal Surgery

Dr. Bhat has over 18 years’ experience in drug discovery and development and prior to founding Reviva, he held research positions at XenoPort, ARYx Therapeutics and Higuchi Biosciences Center in the United States. Dr. Bhat has received a global post-doctoral training at the University of Kansas, USA, the Georg-August-Universität, Göttingen, Germany and the Université du Maine, France. In 1995, he was selected for the Alexander von Humboldt fellowship, an internationally recognized award for young scientists to pursue advanced research in Germany. Dr. Bhat received his Ph.D. in synthetic organic chemistry from the Central University (NEHU), India and has authored over 15 research papers published in peer-reviewed scientific journals. Dr. Bhat is an inventor on more than 100 filed patents and over 35 granted patents

Drug Discovery

The Department of Department of Infectious Diseases / Tropical Medicine, Nephrology and Rheumatology at St. Georg Hospital in Leipzig is about regional focus clinic and competence center for infectious diseases for the state of Saxony

Infectious Diseases & Resarch

Stef Stienstra works internationally for several medical and biotech companies as scientific advisory board member and is also an active reserve-officer of the Royal Dutch Navy in his rank as Commander (OF4). For the Dutch Armed Forces he is CBRNe specialist with focus on (micro)biological and chemical threats and medical- and environmental functional specialist within the 1st CMI (Civil Military Interaction) Battalion of the Dutch Armed Forces. For Expertise France he is now managing an EU CBRN CoE public health project in West Africa. In his civilian position he is at this moment developing with MT-Derm in Berlin (Germany) a novel interdermal vaccination technology as well as a new therapy for cutaneous leishmaniasis for which he has won a Canadian ‘Grand Challenge’ grant. With Hemanua in Dublin (Ireland) he has developed an innovative blood separation unit, which is also suitable to produce convalescent plasma for Ebola Virus Disese therapy. He has finished both his studies in Medicine and in Biochemistry in The Netherlands with a doctorate and has extensive practical experience in cell biology, immuno-haematology, infectous diseaases, biodefense and transfusion medicine. His natural business acumen and negotiation competence helps to initiate new successful businesses, often generated from unexpected combinations of technologies.

Infectious Diseases

An expert in international health initiatives, health in developing nations, HIV/AIDS research

Infection Diseases, Neglected Diseases

Nadia Ameen completed her medical degree from the University of the West Indies, Jamaica. She completed training in Pediatrics at Children’s Hospital Wisconsin and then pursued post-doctoral fellowship in gastroenterology at Yale University School of Medicine. She is the principal investigator of an NIH supported research laboratory at Yale University that studies CFTR and diarrheal diseases for over 20 years. She was the first to recognize a trafficking defect in MVID before a genetic defect was identified. She has authored more than 30 papers in reputed journals and serves as an editorial board member for several journals.

Intestinal Diseases

Deputy Chairman, Intensive Care Department, Consultant, Pulmonary and Critical Care Medicine, Professor, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia, Dr.AlDawood graduate from College of Medicine in Kingdom of Saudi Arabia. Then he completed the Residency in Internal Medicine Program in McMaster University in Canada He obtained Critical Care and Respirology Fellowship Program in McMaster University, Canada (Jul 97-Jun 00). In July 2000, he joined King Abdulaziz Medical City, Riyadh, Saudi Arabia as a Consultant in Critical Care and Pulmonary Medicine up to the present. He is currently the Deputy Chairman of the Intensive Care Department and Professor in King Saud Bin Abdulaziz University for Health Sciences. In addition, he has more than 40 publications including articles in the New England Journal of Medicine (NEJM), JAMA, American Journal of Respiratory Critical Care Medicine, BMC Anesthesiology, and Critical Care Medicine.

Respiratory Critical Care Medicine, Rare Diseases, BMC Anesthesiology,and Critical Care Medicine

Division of Bioinformatics and Biostatistics, FDA

Rare Diseases,chemoinformatics, Predictive toxicologyOrphan Drugs,

Professor Joseph Ndung’u is the Head of FIND’s Neglected Tropical Diseases (NTD) programme. He has a degree in veterinary medicine and surgery (BVM) from the University of Nairobi, and a PhD on the immunopathology of human African trypanosomiasis (HAT or sleeping sickness) from the University of Glasgow’s Veterinary School in Scotland. He became a Visiting Professor of the University in 2001, and has held a similar position at the University of Wisconsin, Madison, USA. In 2013, he became a Corresponding Fellow of the Royal Society of Edinburgh

Tropical Diseases

Romina Ortiz completed her Bachelor’s and Master’s degrees at Johns Hopkins University in Neuroscience and Molecular Microbiology and Immunology, respectively. Her thesis focused on the interplay between the microbiome and hormones in autoimmune disease. She is a co-founder of Rare Genomics Institute (RG), COO and VP of Patient Advocacy at RG. In 2016 she was awarded the Patient Advocacy Leadership award by Sanofi Genzyme. She trains volunteers on the topics of Genetics and Sequencing, directs a Patient Advocacy Program in next generation sequencing and research services to undiagnosed and rare disease patients and currently directs a philanthropic program with Illumina called iHope, offering free whole genome sequencing to children in need of a diagnosis.

Her goal is to integrate phenotypic medical information with genomic data to identify the genetic cause to disease and accelerate the path to treatment and a cure.

Dr. David Dongliang Ge is CEO and President of Apostle. Apostle Inc is a biotechnology company in Sunnyvale, CA focusing on novel bioinformatics-enabled nanotechnologies for cancer early detection. Previously, he was President of BioSciKin Co. and Simcere Diagnostics Co., two global biotechnology companies headquartered in Nanjing, China focusing on the licensing and sales of diagnostic technologies. Between 2011 and 2016, he was Director of Bioinformatics at Gilead Sciences, where he founded and provided leadership to the bioinformatics group and provided the strategic input to related infrastructure and process. Dr. Ge and his group led the phylogenomic analytical support for the critical regulatory approval of Sovaldi, a world-leading anti-HCV drug. In 2014 and 2015, Dr. Ge was invited to be a member of the U.S. National Human Genome Research Institute Special Emphasis Panel. Prior to Gilead, he was appointed as Assistant Professor of Biostatistics and Bioinformatics and Assistant Professor in Medicine at Duke University School of Medicine. He received his Ph.D. of Biostatistics and Genetic Epidemiology from Peking Union Medical College and Chinese Academy of Medical Sciences in 2004. Dr. Ge’s work in discovering the IL28B genetic variants associated with the clinical treatment responses, published in Nature in 2009, has received over 3000 times of citations to date. The invention was licensed to LabCorp and Quest Diagnostics, and has become clinical diagnostic services since then (LabCorp 480630 and Quest AccuType® IL28). The U.S. FDA has cited this ground-breaking discovery in several of the agency’s guidance for industry. Dr. Ge has authored or co-authored over 70 peer-reviewed articles, among which are 5 articles in Nature and 1 in Science, in total receiving over 15,000 citations. Dr. Ge was named by the U.S. Genome Technology magazine as one of the “Rising Stars” in 2009, and by the U.K. Phacilitate as one of the "Top 50 Most Influential People in Big Data" in 2015.

Daniel Cohen , MD Phd, former Professor of Medical Genetics in Paris University has authored more than 150 peer reviewed papers in hire wired Journal , including the first integrated map of the Human Genome back in the 90’s. While he has discovered or co discovered numerous genes for rare and common diseases, he has also pioneered several key technologies like Large Scale Biology at Genethon, he cofounded in France, but also Pharmacogenomics, Genome Wide Association Studies and Network Pharmacology. He was a confounder of Millenium pharmaceuticals in Boston, MA. He is now Chairman, CEO and cofounder of the France Based company, Pharnext, focusing on treatment of unmet Neurodegenerative disorders by using Network Pharmacology.

orphan genetic

Dr. Harsha Rajasimha has over 15 years of experience and widely recognized in the field of Genomics, systems biology data integration standards, BigData analytics, data enabled life sciences, and precision medicine for cancer and rare disease diagnosis. Dr. Rajasimha is currently global head of life sciences R&D for NTT DATA Services (formerly Dell Services). He co-directs the center for metabolic and rare diseases at George Mason University. Earlier, he led the global strategy and business development for Strand Life Sciences, a CAP/CLIA laboratory and Bioinformatics powerhouse and precision medicine diagnostics company, between 2013 and 2016. Dr. Rajasimha founded Jeeva Informatics Solutions (www.Jeevadx.com) in 2013, a cloud based genomic data informatics Company that received the ‘Bioscience Company of the Year 2014’ award from Montgomery County, MD. He is co-founder and board member of the non-profit organization for rare diseases India (www.ordindia.org) and established mechanisms to accelerate rare disease diagnosis, public health policies and accessibility of treatments for patients in India. Dr. Rajasimha has led the development of some of the largest genomics projects including PathogenPortal, Pathosystems resource integration center, Cancer Biomedical Informatics Grid (caBIG), LIMS implementation at the FDA Office of Regulatory Affairs, architected Genome Explorer® a web-based platform for next-generation sequencing (NGS) data analysis for Genome International Corporation and Cyberinfrastructure development for National Eye Institute's genomics program. His contributions to the NGS program were recognized by NEI director’s innovation award in 2012. Dr. Rajasimha has authored over 15 peer-reviewed articles, book chapters, inventor on patents and is often invited speaker at international conferences and executive consultant/advisor to a number of biotech startups. He has contributed to global data standards initiatives such as BioPAX, DELSAGlobal, personalized medicine coalition, and the global alliance for genomics and health. He earned baccalaureate degree in computer science engineering from Bangalore University, Masters in Computer Science & Bioinformatics and Doctoral degree in interdisciplinary program genetics, bioinformatics and computational biology from Virginia Tech.

.

Amrik Sahota is a professor in the Department of Genetics, Rutgers University, Piscataway, NJ. He is also a clinical professor in the Department of Pathology and Laboratory Medicine and in the Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. Dr. Sahota is a fellow of the American College of Medical Genetics and Genomics, National Academy of Clinical Chemistry, Royal Society of Biology (UK), and the Royal College of Pathologists (UK). He is board-certified in clinical molecular genetics by the American Board of Medical Genetics and Genomics and in molecular diagnostics by the American Board of Clinical Chemistry.

Dr. Sahota’s research interests are in genetic disorders of urolithiasis, mouse models for human disease, and molecular diagnostics.

Stella Blackburn has spent over 30 years in pharmacovigilance and pharmacoepidemiology in both regulatory and industry environments. Trained in medicine at Cambridge and London Universities she has an MSc in epidemiology from the London School of Hygiene and Tropical Medicine. At the European Medicines Agency she was responsible for developing risk management for Europe and was the lead author of the guidelines. She is passionate about optimizing the benefit risk balance of medicines and to helping bring medicines to patients with unmet medical needs – particularly those with rare diseases. She is a Visiting Scientist at the Center for Biomedical Innovation, Massachusetts Institute of Technology where she continues work on innovative methods for bringing medicines to market. She is a Fellow of the Royal College of Physicians of Edinburgh and a Fellow and Past President of the International Society of Pharmacoepidemiology.

.

Dr. Jacques P. Tremblay received a PhD in Neuroscience from the University of California at San Diego in 1974. Since that time, he has been at Laval University as a postdoctoral researcher, Professor and Director of the Department of Anatomy. He is currently Full Professor in the Department of Molecular Medicine. He has published over 250 scientific articles on hereditary diseases. He has worked specifically on myoblast transplantation as a treatment for Duchenne muscular dystrophy. For the last 3 years he also worked on gene correction with the CRISPR/Cas9 technology for Duchenne muscular dystrophy, Friedreich's Ataxia and Alzheimer’s disease.

.

Dr. Anton Yuryev received PhD in Molecular Biology and Genetics at Johns Hopkins University, Baltimore USA where he discovered proteins physically linking gene transcription and mRNA processing in eukaryotic cells. He has over 20 years of experience in bioinformatics. After finishing his post-doctoral training at Novartis Inc Dr. Yuryev worked as Senior Scientist at InforMax, then continued at Orchid Bioscience as Senior Bioinformatics Analyst, and then founded Ariadne Genomics where he worked as Senior Director of Application Science and participated in the development of natural language processing technology and Pathway Studio software. Dr. Yuryev has published more than 50 scientific publications, edited three scientific books, and authored several algorithms for primer design and pathway analysis. After Elsevier acquisition of Ariadne Genomics Dr. Yuryev works as Professional Services Director at Elsevier and responsible for development of targeted bioinformatics solutions using Elsevier software and knowledgebases in the areas of drug development, personalized medicine and agrobiology.

Dr. Yuryev’s research interests involve developing statistical models for drug repurposing, drug target prioritization and therapy optimization based on molecular mechanisms for all kinds of human malignancies including rare and complex diseases.

Daniel Cohen , MD Phd, former Professor of Medical Genetics in Paris University has authored more than 150 peer reviewed papers in hire wired Journal , including the first integrated map of the Human Genome back in the 90’s. While he has discovered or co discovered numerous genes for rare and common diseases, he has also pioneered several key technologies like Large Scale Biology at Genethon, he cofounded in France, but also Pharmacogenomics, Genome Wide Association Studies and Network Pharmacology. He was a confounder of Millenium pharmaceuticals in Boston, MA. He is now Chairman, CEO and cofounder of the France Based company, Pharnext, focusing on treatment of unmet Neurodegenerative disorders by using Network Pharmacology.

orphan genetic

Serge Braun, PharmD, is Scientific Director of AFM-Telethon since 2005, the French Muscular dystrophy Association, and President of Genosafe, a CRO company dedicate to QC of biotherapeutic products. He obtained his degree in Pharmacy and a Ph.D in Pharmacology from the Louis Pasteur University of Strasbourg, France; was a postdoctoral fellow at the Neuromuscular Center, School of Medicine of the University of Southern California in Los Angeles, USA.

.

In 2015 Dr. Arneric joined the Critical Path Institute as Executive Director of the Coalition Against Major Diseases (CAMD), a consortium focused on developing Drug Development Tools for advancing innovative treatments of Alzheimer’s disease and related dementias. Previously he was VP Research/Preclinical Development (Neuromed Pharmaceuticals), CSO of the Pain/Migraine Drug Hunting Team (Lilly), and held senior management positions at Pfizer, Pharmacia, DuPont Pharmaceuticals, and Abbott. He has extensive leadership and scientific expertise in the areas of neurology, pain, psychiatry and urology, and over the last 25 years his teams have delivered more than 30+ drug candidates into clinical development.

.

Dr Stephen Shrewsbury is currently Executive Vice President of Development and Chief Medical Officer at Fortuna Fix, leading their novel cellular technology into multiple clinical programs focused on Regenerative Medicine, several of which are rare diseases. A UK trained physician, Dr Shrewsbury first joined Glaxo 23 years ago. He moved to lead inhaled antibiotic programs at Chiron Corporation (in Cystic Fibrosis and other rare diseases) before becoming CMO sequentially to MAP Pharmaceuticals, Adamas Pharmaceuticals, AVI BioPharma (now Sarepta Therapeutics – where he opened their first IND for eteplirsen in Duchenne Muscular Dystrophy and planned their oligomer programs against Ebola and Marburg Hemorrhagic Fevers) and Aquinox Pharmaceuticals. He has now moved from Drugs (and Devices) and Oligonucleotides to lead programs with directly reprogrammed precursor cells and tackle many rare, and currently untreatable, diseases with great social and healthcare impact. He is author of Defy Your DNA and over 70 scientific papers, holds several patents and contributed to many awarded grants – mostly for work on rare diseases.

.

Dr. Sahota works at Rutgers University in the following capacities: (i) professor in the Department of Genetics, (ii) director of scientific programs and director of the Clinical Genomics Laboratory, RUCDR Infinite Biologics; (iii) clinical professor and laboratory director in the Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School (RWJMS); and (iv) clinical professor in the Division of Urology, RWJMS. Dr. Sahota’s research is focused on the molecular pathology of inherited urinary tract stone disease. He and his colleagues have characterized the molecular bases of adenine phosphoribosyltransferse (APRT) deficiency in the vast majority of Caucasian patients with this disorder.

Dr. Sahota’s research is focused on the molecular pathology of inherited urinary tract stone disease.

Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy (Duchenne). Their mission is to end Duchenne. They accelerate research, raise their voices in Washington, demand optimal care for all young men, and educate the global community.

.

Prof Annemieke Aartsma-Rus obtained her PhD aged 27 at Leiden University (the Netherlands) in 2005. She became group leader in 2007 and is currently a professor of Translational Genetics at Leiden University Medical Center, the Netherlands. She currently chairs the TREAT-NMD Alliance (an infrastructure network for clinical trial readiness for neuromuscular disorders) and a networking Action (funded by Cooperation of Science and Technology (COST). She has published more than 100 papers in peer reviewed journals, has written multiple book chapters and has generated and maintains pages to explain Duchenne therapies in lay terms to the patient community. In 2009 she received the Duchenne award from the Dutch Duchenne Parent Project for her dedication to the field.

Duchenne muscular dystrophy

Glenn S Tillotson has over 30 years pharmaceutical experience in pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. He has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and several other agents. He is a SVP of Medical Affairs where he is preparing for the launch of solithromycin for community acquired bacterial pneumonia. He has published more than 170 peer-reviewed manuscripts and is on several journal Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine, Expert Reviews in Anti-infective Therapy and F1000.

Infectious diseases

Joanna Zajkowska is currently working at Medical University of Białystok, Poland and carries Clinical Research on infectious diseases, especially on tick-borne diseases and nervous system diseases. She is an expert in internal medicine, infectious diseases, public health and epidemiology. She is a Member of ISW-TBE, Wien Austria (International Scientific Working group on Tick-Borne Encephalitis and ESGBOR (ESCMID-European Society of Clinical Microbiology and Infectious Diseases). She has published more than 200 papers in reputed journals and serving as a Reviewer in many journals.

Clinical Research on infectious diseases, especially on tick-borne diseases and nervous system diseases

Stef Stienstra is a strategic and creative Consultant in Biomedical Science with a parallel career as a Commander of the reserve of the Royal Dutch Navy. For the Dutch Armed Forces he has responsibility for the counter measures in CBNRe threats and (Medical) consequence management both in a military and a civilian (terrorism) setting. He is a strategic functional specialist for “Health & Environment” of the 1-Civil-Military-Interaction Command (1-CMI) of the Dutch Armed Forces and for 2015 also in the NATO Response Force (NRF), which is in 2015 the responsibility of the 1-German-Netherlands-Corps (1-GNC). In his civil career he works internationally as Consultant or as Scientific Supervisory Board Member for several medical and biotech companies, merely involved in biodefense. He is also a Visiting Professor for Punjab University in Pakistan and Rhein-Waal University in Germany. He has completed his studies in Medicine and in Biochemistry at the University of Groningen in The Netherlands and has extensive practical experience in cell biology, immuno-hematology, biodefense and transfusion medicine. His natural business acumen and negotiation competence helps to initiate new successful businesses, often created out of unexpected combinations of technologies. His good understanding of abstract science combined with excellent skills in the communication of scientific matters to non-specialists, helps him with strategic consulting at top level management.

Ebola

Eugenie Bergogne-Berezin is a Professor of Clinical Microbiology at University Diderot, Paris. She has studied MD in Medicine and PhD in Sciences in the early 1970s. She is a Chief of Department of Clinical Microbiology and research group, University Bichat Claude-Bernard and developed research on Acinetobacter spp., (nosocomial pathogen, pathogenicity, resistance), pharmacology of antibiotics, tissue distribution (lungs, brain, bronchi), research on intestinal ecology, jejunal flora and bacterial adhesion. She is an Adviser to pharmaceutical companies, expert in pharmacology-toxicology for the Ministry of Health, expert for international journals. She has developed a journal Antibiotics, (Elsevier). She has published 6 medical books, many chapters in international infectious diseases books, 200 articles in scientific journals.

Antibiotics

K C Santosh worked as a research fellow at the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). He worked as a postdoctoral research scientist at the LORIA research centre, Universite de Lorraine in direct collaboration with industrial partner ITESOFT, France, for 2 years. He also worked as a research scientist at the INRIA Nancy Grand Est research centre for 3 years, until 2011. K C Santosh has demonstrated expertise in pattern recognition, image processing, computer vision and machine learning with various applications in handwriting recognition, graphics recognition, document information content exploitation, medical image analysis and biometrics. He published more than 60 research articles, including a book section in encyclopedia of electrical and electronics engineering.

Electrical and electronics engineering

Fernanda De Freitas Anibal had her PhD from University of São Paulo, Brazil in Basic and Applied Immunology. She is a Principal Investigator at Laboratory of Parasitology (Federal University of São Carlos) seeks new tools for the treatment, prevention and diagnostics for infectious diseases. Currently, they are working with two plants and six enzymes and their effects against schistosomiasis mansoni and toxocariasis, about the treatment of the infectious diseases, their group studies effects of plants (extracts) and their isolated fractions in order to evaluate the anti-parasitic and anti-inflammatory effects and for infectious disease prevention, moreover have been working on the evaluation of the proteins of the parasite that has been potential to induce immune responses that decrease the parasite burden.

Immune Responses

Lalit Garg has received his PhD degree from the University of Ulster, UK in 2010. He has received his first degree in Electronics & Communication Engineering from the Barkatullah University, India in 1999 and Postgraduate degree in Information Technology from ABV-IIITM, Gwalior, India in 2001. He is currently a Senior Lecturer in Computer Information Systems at the University of Malta, Malta. He was a Researcher at the Nanyang Technological University, Singapore and at the University of Ulster, UK. His research interests include missing data handling, machine learning, data mining and their applications especially in the healthcare domain. He has published more than 60 technical papers in refereed journals and conferences.

Electronics and communication engineering

Junie Lia Monica is an MD, Ph D, Professor, Head Microbiology Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania. She is a Coordinator of resident doctor’s in the Laboratory Medicine specialty and Leadership PhD doctor’s thesis in Medicine field. She is a Board Member of European professional Societies ESCMID (ESGCP Study Groups), Society of Chemotherapy, Scientia Parasitologica Pro Vita and is a Reviewer of international reviews, Member of International organizations, Director/Coordinator in research projects. She has more than 63 papers published in full in international journals and is an editorial board member of national reviews. She is an Organizer/President, Keynote, Invited Speaker and Chair of International and National Congresses.

Microbiology

Thomas D Licker has a BS in Environmental Science from Slippery Rock University and has over 20-years experience in handling event driven hazardous materials and biological response actions. He holds an accredited certification as a Council Certified Environmental Infection Control Remediator recognized by the Council for Engineering and Scientific Boards. He is the Director of Infection Control Technologies, a premier bioremediation services company and serves as the Director of Operations for Decontamination Professionals International.

Infection control technologies

Francis J Castellino is the Kleiderer-Pezold Professor of Biochemistry and Director of the WM Keck Center for Transgene Research at the University of Notre Dame, USA. He has coauthored more that 400 peer reviewed manuscripts.

Hemostasis system

Stef Stienstra is a strategic and creative Consultant in Biomedical Science with a parallel career as a Commander of the reserve of the Royal Dutch Navy. For the Dutch Armed Forces he has responsibility for the counter measures in CBNRe threats and (Medical) consequence management both in a military and a civilian (terrorism) setting. He is a strategic functional specialist for “Health & Environment” of the 1-Civil-Military-Interaction Command (1-CMI) of the Dutch Armed Forces and for 2015 also in the NATO Response Force (NRF), which is in 2015 the responsibility of the 1-German-Netherlands-Corps (1-GNC). In his civil career he works internationally as Consultant or as Scientific Supervisory Board Member for several medical and biotech companies, merely involved in biodefense. He is also a Visiting Professor for Punjab University in Pakistan and Rhein-Waal University in Germany. He has completed his studies in Medicine and in Biochemistry at the University of Groningen in The Netherlands and has extensive practical experience in cell biology, immuno-hematology, biodefense and transfusion medicine. His natural business acumen and negotiation competence helps to initiate new successful businesses, often created out of unexpected combinations of technologies. His good understanding of abstract science combined with excellent skills in the communication of scientific matters to non-specialists, helps him with strategic consulting at top level management.

Ebola

Rachel Groppo has completed her PhD in the laboratory of Dr. Ann Palmenberg at the University of Wisconsin, USA. After completing her Post doctorate at the University of Massachusetts Medical School, she has joined Sanofi Pasteur. Currently she is a Virology Manager at Sanofi Pasteur North American Research.

Virology

Eugenie Bergogne-Berezin is a Professor of Clinical Microbiology at University Diderot, Paris. She has studied MD in Medicine and PhD in Sciences in the early 1970s. She is a Chief of Department of Clinical Microbiology and research group, University Bichat Claude-Bernard and developed research on Acinetobacter spp., (nosocomial pathogen, pathogenicity, resistance), pharmacology of antibiotics, tissue distribution (lungs, brain, bronchi), research on intestinal ecology, jejunal flora and bacterial adhesion. She is an Adviser to pharmaceutical companies, expert in pharmacology-toxicology for the Ministry of Health, expert for international journals. She has developed a journal Antibiotics, (Elsevier). She has published 6 medical books, many chapters in international infectious diseases books, 200 articles in scientific journals.

Antibiotics

Fernanda De Freitas Anibal had her PhD from University of São Paulo, Brazil in Basic and Applied Immunology. She is a Principal Investigator at Laboratory of Parasitology (Federal University of São Carlos) seeks new tools for the treatment, prevention and diagnostics for infectious diseases. Currently, they are working with two plants and six enzymes and their effects against schistosomiasis mansoni and toxocariasis, about the treatment of the infectious diseases, their group studies effects of plants (extracts) and their isolated fractions in order to evaluate the anti-parasitic and anti-inflammatory effects and for infectious disease prevention, moreover have been working on the evaluation of the proteins of the parasite that has been potential to induce immune responses that decrease the parasite burden.

Immune responses

Joanna Zajkowska is currently working at Medical University of Białystok, Poland and carries Clinical Research on infectious diseases, especially on tick-borne diseases and nervous system diseases. She is an expert in internal medicine, infectious diseases, public health and epidemiology. She is a Member of ISW-TBE, Wien Austria (International Scientific Working group on Tick-Borne Encephalitis and ESGBOR (ESCMID-European Society of Clinical Microbiology and Infectious Diseases). She has published more than 200 papers in reputed journals and serving as a Reviewer in many journals.

Tick-borne diseases and nervous system diseases

Ashok Kapse is a consulting Pediatrician practicing in the city of Surat in the Gujarat state of India, besides owning a private pediatric hospital he is also Head of the Pediatric Department at a prestigious Mahavir Super Specialty Hospital. After finishing graduation (MBBS) he did MD in Pediatrics. Initially he has worked as a Professor of Pediatrics at Medical College Surat, later he opted out for private practice however pursued academic interest. He developed special interest and skill in infectious diseases. He is a recipient of many oration awards and delivered hundreds of lectures on dengue, malaria, typhoid and antibiotic uses across India. He has decorated many a posts in medical fields: President of Surat City Branch of Indian Academy of Pediatrics (IAP), President of Gujarat State Branch of IAP and National President of Infectious Diseases Branch of IAP are few of them. He is an avid Clinical Photographer; his photos figure into various books and atlases including the prestigious atlas of infectious diseases published by American Academy of Pediatrics. He has published umpteen articles in peer reviewed journals.

Pediatric infectious diseases

Stephen Mortlock X is the Global Infectious Diseases and Microbiology Liaison at the Q2 Solutions Laboratory in UK. Prior to joining Q2 Solutions, he was the Chief Microbiologist at the Shaukat Khanum Memorial Cancer Hospital and Research Centre in Lahore, Pakistan and was awarded a DSc for his work setting up an antenatal screening program for the indigent population. He with his colleagues has published over 40 papers on an eclectic mix of subjects from enteric pathogens, food science and saliva cotinine. He has also worked for the Health Protection Agency in the UK and spent time in the Middle East.

Global infectious diseases and microbiology

Junie Lia Monica is an MD, Ph D, Professor, Head Microbiology Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania. She is a Coordinator of resident doctor’s in the Laboratory Medicine specialty and Leadership PhD doctor’s thesis in Medicine field. She is a Board Member of European professional Societies ESCMID (ESGCP Study Groups), Society of Chemotherapy, Scientia Parasitologica Pro Vita and is a Reviewer of international reviews, Member of International organizations, Director/Coordinator in research projects. She has more than 63 papers published in full in international journals and is an editorial board member of national reviews. She is an Organizer/President, Keynote, Invited Speaker and Chair of International and National Congresses.

Microbiology

Maria Luisa G Daroy is a Scientist at the Research and Biotechnology Division of St. Luke’s Medical Center and Assistant Professor in the MS Molecular Medicine Program of the St. Luke’s College of Medicine-WHQ Memorial. She has published more than 20 papers on dengue, Japanese encephalitis, chikungunya, eye infections, dementia, diabetes and coronary artery disease. She was the Chair of the Board of Examiners of the Philippine Academy for Microbiology from 2013-2015 and authored a book chapter on Philippine microbiology research. Researches include dengue, chikungunya, diarrhea, CNS infections, pathogen genomics, antimicrobial resistance, plant antivirals, molecular diagnostics and genetics of CVD, thyroid cancer and dementia.

Dengue, chikungunya, diarrhea , CNS infections, pathogen genomics, antimicrobial resistance, plant antivirals, molecular diagnostics, genetics of CVD, thyroid cancer and dementia

Maria Del Rosario Davalos Gamboa has acquired her Pharmaceutical Biochemistry degree from the University of San Simon. She has started working at the University of San Simon in the Faculty of Medicine at the Laboratory of Nuclear Medicine and later from August 1992 continued working as a Teaching Research Assistant till 1998. From 2009 to 2010, she was the Director of the Research Institute of the Faculty of Dentistry UMSS and in 1997 won a competency exam at the Faculty of Dentistry UMSS in Biochemistry and appointed as a Professor. She is currently a Legal Representative and owner partner (in a greater proportion than 51% of shares) of the International Associated Factory oils and coals SRL ACECAB, in the city of Santa Cruz, Bolivia, whose principal activity is to generate cosmetic oils and charcoal.

Cancer research

M Khalid Ijaz received DVM, MSc (Honors) from University of Agriculture, Faisalabad, Pakistan and completed Ph.D. in Microbiology and Immunology in 1985 at University of Ottawa, Canada. He did his post-doctoral work at the Vaccines and Infectious Disease Organization (VIDO), Canada. Currently, he’s Research Fellow at RB, Montvale, N.J. and Adjunct Associate Professor at The City University of New York (CUNY). His research focuses on human pathogenic microbial agents’ spread via the environment and mitigational role of hygiene agents. He is an active member of various scientific organizations including American Society for Microbiology, American Society for Virology, ASTM-International, Association of Professionals for Infection Control and Epidemiology and International Society for Infectious Diseases.

Human pathogenic microbial agents

Irina Magdalena Dumitru is an MD, PhD, Associate Professor, "Ovidius" University, Constanta, Romania, Faculty of Medicine. Senior Specialist in Infectious Diseases at Clinical Infectious Diseases Hospital, Constanta. Director of research and development (2006 – 2010) at Clinical Infectious Diseases Hospital, Constanta, in present I am Director of Research Department at Ovidius" University” Constanta. In recent years I am focused on the parasitological, tropical diseases, chronic hepatitis and HIV/AIDS research. In present I am NCP Health Romania for Horizon 2020 program. I am involved in many research projects, clinical trials and I have published numerous scientific articles (more than 95 papers and chapters in medical science journals and books). I am president of the Romanian Association of Parasitology, Constanta and I am member of many scientific societies (EACS, IAS, BENA, Romanian Association of Infectious Diseases, Romanian Association of Study Liver, Romanian Society of Microbiology).

Tropical infectious diseases

Stef Stienstra is a strategic and creative Consultant in Biomedical Science with a parallel career as a Commander of the reserve of the Royal Dutch Navy. For the Dutch Armed Forces he has responsibility for the counter measures in CBNRe threats and (Medical) consequence management both in a military and a civilian (terrorism) setting. He is a strategic functional specialist for “Health & Environment” of the 1-Civil-Military-Interaction Command (1-CMI) of the Dutch Armed Forces and for 2015 also in the NATO Response Force (NRF), which is in 2015 the responsibility of the 1-German-Netherlands-Corps (1-GNC). In his civil career he works internationally as Consultant or as Scientific Supervisory Board Member for several medical and biotech companies, merely involved in biodefense. He is also a Visiting Professor for Punjab University in Pakistan and Rhein-Waal University in Germany. He has completed his studies in Medicine and in Biochemistry at the University of Groningen in The Netherlands and has extensive practical experience in cell biology, immuno-hematology, biodefense and transfusion medicine. His natural business acumen and negotiation competence helps to initiate new successful businesses, often created out of unexpected combinations of technologies. His good understanding of abstract science combined with excellent skills in the communication of scientific matters to non-specialists, helps him with strategic consulting at top level management.

Ebola

Amr Ismail is an MBBCh, MSc, MD, MACP, FISQua, FABAM, CHPI, Consultant Dermatologist, received his Doctorate of Dermatology in 1998, Faculty of Medicine, Cairo University, Egypt, Fellow of the American Board of Aesthetic Medicine (ABAM), USA, Fellow of International Society for Quality in Healthcare (ISQua), Ireland, Certified Professional Health Performance Improvement, AIHQ, USA, Member of American College of Health Executives (ACHE), USA and Member of American College of Physicians (ACP).

Vaccines for HFMD

Ashok Kapse is a consulting Pediatrician practicing in the city of Surat in the Gujarat state of India, besides owning a private pediatric hospital he is also Head of the Pediatric Department at a prestigious Mahavir Super Specialty Hospital. After finishing graduation (MBBS) he did MD in Pediatrics. Initially he has worked as a Professor of Pediatrics at Medical College Surat, later he opted out for private practice however pursued academic interest. He developed special interest and skill in infectious diseases. He is a recipient of many oration awards and delivered hundreds of lectures on dengue, malaria, typhoid and antibiotic uses across India. He has decorated many a posts in medical fields: President of Surat City Branch of Indian Academy of Pediatrics (IAP), President of Gujarat State Branch of IAP and National President of Infectious Diseases Branch of IAP are few of them. He is an avid Clinical Photographer; his photos figure into various books and atlases including the prestigious atlas of infectious diseases published by American Academy of Pediatrics. He has published umpteen articles in peer reviewed journals.

Pediatric infectious diseases